Edwards lifesciences corporation
EW 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
EW 近期報酬表現
0.90%
Edwards lifesciences corporation
1.19%
同產業平均
0.91%
S&P500
與 EW 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
ALGN | Align technology, inc. | 2 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
SYK | Stryker corporation | 3 分 | 2 分 | 2 分 | 3 分 | 4 分 | |
IDXX | Idexx laboratories incorporated | 4 分 | 1 分 | 4 分 | 2 分 | 1 分 | |
RMD | Resmed inc. | 5 分 | 5 分 | 4 分 | 2 分 | 4 分 | |
COO | Cooper companies inc | 4 分 | 3 分 | 1 分 | 3 分 | 3 分 |
- ALGN Align technology, inc.價值 2 分趨勢 3 分波段 2 分籌碼 2 分股利 1 分查看更多
EW 公司資訊
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.